Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STAT
obligations may continue. See	

TEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) (First) (Middle) C/O KALA PHARMACEUTICALS, INC. 490 ARSENAL WAY, SUITE 120 (Street) WATERTOWN MA 02472 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Da	1. Name and Address of Reporting Person* <u>Brazzell Romulus K</u>						2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [KALA]									heck	cionship of Reportin all applicable) Director Officer (give title		ng Pei	rson(s) to Is 10% O Other (wner
4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person X Form filed by More than One Reporting Pers	C/O KALA PHARMACEUTICALS, INC.															X	below	ow)		below)	, ,
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Disposed Of (D) (Instr. 3, 4 and Disposed Of (D) (Instr. 3) 3. Transaction (Code (Instr. 4) 4. Amount (A) or Disposed Of (D) (Instr. 3, 4 and Disposed Of (D) (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Disposed Of (D) (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Disposed Of (D) (Instr. 4) 5. Number of Date (Month/Day/Year) 2. Conversion Of Date (Month/Day/Year) 2. Conversion Of Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 4) 5. Number of Derivative Securities (Month/Day/Year) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 4) 5. Number of Derivative Securities (Instr. 5) 8. Price of Derivative Securities (Instr. 5) 8. Price of Derivative Securities (Instr. 5) 8. Price of Derivative Securities (Instr. 5) 9. Number of Derivative Securities (Instr. 5) 1. Title of Derivative Securities (Instr. 4) 1. Title of Date (Instr. 4) 2. Derivative Security (Instr. 3) 3. Transaction (Instr. 4) 4. Derivative Securities (Instr. 4) 4. Derivative Securities (Instr. 4) 4. Derivative Securities (Instr. 4) 5. Number of Derivative Securities (Instr. 5) 8. Price of Derivative Securities (Instr. 4) 9. Number of Derivative Securities (Instr. 4) 9. Number of Derivative Securities	(Street) WATER	ΓOWN M	IA 0			4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Common Stock 10/26/2021 3. Transaction Code (Instr. 8) 3. Transaction (D) (Instr. 3, 4 and 5) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 7. Nature of Indirect (D) or Indirect (D) or Indirect (D) or Indirect (D) or Indirect (D) (Instr. 4) 8. Price of Derivative Security (Instr. 3) 2. Conversion Or Exercise Provided (A) or Disposed Of (D) (Instr. 4) 8. Price of Derivative Security (Instr. 5) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities (Instr. 5) 1. Title of Derivative Security (Instr. 3) 1. Title of Derivative Security (Instr. 3) 1. Transaction Date (Month/Day/Year) 1. Title of Derivative Security (Instr. 3) 1. Transaction Date (Month/Day/Year) 1. Title of Derivative Security (Instr. 3) 1. Transaction Date (Month/Day/Year) 2. Conversion Or Exercise Date (Month/Day/Year) 1. Title of Derivative Securities (Instr. 5) 2. Conversion Or Exercise Date and Expiration Date (Month/Day/Year) 1. Nature of Disposed of (D) (Instr. 4) 1. Title of Derivative Securities (Instr. 5) 1. Nature of Disposed Of (D) (Instr. 4) 1. Nature of Disposed Of (D) (Instr. 4) 1. Nature of Disposed Of (D) (Instr. 4) 2. Conversion Or Exercise Acquired (A) or Disposed Of (D) (Instr. 4) 3. Transaction or Exercise Acquired (A) or Disposed Of (D) (Instr. 4) 3. Transaction or Exercise Acquired (A) or Disposed Of (D) (Instr. 4) 3. Transaction or Exercise Acquired (B) or Disposed Of (D) (Instr. 4) 3. Transaction or Exercise Acquired (B) or Disposed Of (D) (Instr. 4) 4. Securities Or Disposed Of (D) (Instr. 4) 5. Number of Derivative Securities (Instr. 5) 9. Number of Or Or Exercise Acquired (B) or Disposed Of (D) or Indirect (D) (Instr. 4) 1. Nature or Disp	(City)	(5	`																		
Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Securities Securities Securities (I) (Instr. 4) Table II - Derivative Security (Instr. 3)			Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uirec	l, Dis	posed of	f, o	r Ben	efici	ally	Own	ed			
Common Stock 10/26/2021 S 12,757(1) D \$1.8(2) 291,849(3) D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Securities Onder (Month/Day/Year) Security (Instr. 3) Amount (A) or (D) Price Transaction(s) (Instr. 3 and 4) D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Securities (Month/Day/Year) Security (Instr. 3) Amount of S. Number of Derivative Securities (Month/Day/Year) Securities Underlying Derivative Securities Underlying Derivative Securities (Month/Day/Year) Security (Instr. 5) Amount of Derivative Securities (Instr. 4) Amount of Securities (Instr. 4) Amount of Derivative Securities (Instr. 4)	Date					Execution Date, /Year) if any			Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)					4 and Secu Bend Own		rities ficially ed Following		n: Direct or Indirect	of Indirect Beneficial Ownership		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) Price of Derivative Security Securities S										v	Amount	(A) or (D)		Price		Transaction(s)				(IIISti. 4)	
(e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) Price of Derivative Security Se	Common Stock 10/26/2									S		12,757 ⁽¹⁾ D		D	\$1.8	3(2)	291,849 ⁽³⁾			D	
Derivative Security (Instr. 3) Price of Derivative Security (Security Conversion of Derivative Security (Instr. 3) Price of Derivative Security Securities Security (Instr. 3 and 4) Security Security Securities Security (Instr. 4) Securities Security Securities Security (Instr. 4) Securities Securities Security (Instr. 4) Securities Securities Security (Instr. 4) Securities Securitie																					
	Derivative Security	erivative Conversion ceurity or Exercise (Month/Day/Year) Price of Derivative Execution Date, if any (Month/Day/Year)			ion Date,	Transaction Code (Instr.		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date				Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Deri Seci	erivative ecurity	derivative Securities Beneficially Owned Following Reported Transaction	y	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.79 to \$1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- 3. Includes 77,500 unvested RSUs and 3,644 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 30, 2021.

/s/ Eric Trachtenberg, 10/28/2021 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.